Literature DB >> 8279818

Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection.

G H Tignor1, C A Hanham.   

Abstract

After intraperitoneal (i.p.) infection of infant mice with CCHF virus, virus titers in liver remained significantly higher than in other organs except blood (serum). Within the liver, virus antigen was first found by immunofluorescence (IFA) in Kupffer cells followed by more extensive hepatic spread. Later, virus was found in other organs including brain and heart. Ribavirin treatment significantly reduced infant mouse mortality and extended the geometric mean time to death. Ribavirin treatment reduced CCHF virus growth in liver and significantly decreased, but did not prevent, viremia. Despite a substantial viremia, infection of other organs including brain and heart was not detected in ribavirin-treated mice. A hepatotropic virus subpopulation with less neurovirulence than the parent was isolated from liver of ribavirin-treated mice (single dose, 100 mg/kg). After serial passage in placebo-treated mice, the exclusive hepatotropism was lost.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279818      PMCID: PMC7172876          DOI: 10.1016/0166-3542(93)90040-p

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  29 in total

1.  Further studies on the serological relationships of group C arthropod-borne viruses and the application of these relationships to rapid identification of types.

Authors:  R E SHOPE; O R CAUSEY
Journal:  Am J Trop Med Hyg       Date:  1962-03       Impact factor: 2.345

2.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

3.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

Review 4.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

5.  Intrasplenic primary immunization for the production of monoclonal antibodies.

Authors:  M Spitz; L Spitz; R Thorpe; E Eugui
Journal:  J Immunol Methods       Date:  1984-05-11       Impact factor: 2.303

6.  Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen.

Authors:  M K Ho; T A Springer
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

7.  A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures.

Authors:  B W van de Wal; J R Joubert; P J van Eeden; J B King
Journal:  S Afr Med J       Date:  1985-11-09

8.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

9.  Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro.

Authors:  S K Wray; B E Gilbert; V Knight
Journal:  Antiviral Res       Date:  1985-02       Impact factor: 5.970

10.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

View more
  21 in total

1.  Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function.

Authors:  Eric Bergeron; César G Albariño; Marina L Khristova; Stuart T Nichol
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 2.  Recent advances in research on Crimean-Congo hemorrhagic fever.

Authors:  Anna Papa; Ali Mirazimi; Iftihar Köksal; Augustin Estrada-Pena; Heinz Feldmann
Journal:  J Clin Virol       Date:  2014-10-22       Impact factor: 3.168

3.  Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.

Authors:  Dennis A Bente; Judie B Alimonti; Wun-Ju Shieh; Gaëlle Camus; Ute Ströher; Sherif Zaki; Steven M Jones
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

4.  Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy.

Authors:  Marko Zivcec; David Safronetz; Dana Scott; Shelly Robertson; Hideki Ebihara; Heinz Feldmann
Journal:  J Infect Dis       Date:  2013-02-15       Impact factor: 5.226

Review 5.  Immunobiology of Crimean-Congo hemorrhagic fever.

Authors:  Sergio E Rodriguez; David W Hawman; Teresa E Sorvillo; T Justin O'Neal; Brian H Bird; Luis L Rodriguez; Éric Bergeron; Stuart T Nichol; Joel M Montgomery; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2022-01-11       Impact factor: 10.103

6.  A patient with Crimean-Congo hemorrhagic fever serologically diagnosed by recombinant nucleoprotein-based antibody detection systems.

Authors:  Qing Tang; Masayuki Saijo; Yuzhen Zhang; Muer Asiguma; Dong Tianshu; Lei Han; Bawudong Shimayi; Akihiko Maeda; Ichiro Kurane; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

Review 7.  Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis.

Authors:  Karla Soares-Weiser; Sherine Thomas; Gail Thomson; Paul Garner
Journal:  BMC Infect Dis       Date:  2010-07-13       Impact factor: 3.090

Review 8.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

9.  Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin.

Authors:  Olivier Flusin; Solenne Vigne; Christophe N Peyrefitte; Michèle Bouloy; Jean-Marc Crance; Frédéric Iseni
Journal:  Virol J       Date:  2011-05-21       Impact factor: 4.099

10.  Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment.

Authors:  Helena C Maltezou; Anna Papa
Journal:  BMC Med       Date:  2011-12-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.